Compare Citius Pharmaceuticals Inc (CTXR) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Meta Platforms Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Meta Platforms Inc trades at $718.64 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 135095.4× Citius Pharmaceuticals Inc's market cap, and Meta Platforms Inc pays a 0.29% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Meta Platforms Inc for 127 Days on average.
| CTXR | META | |
|---|---|---|
Market Cap | $13.62M | $1.84T |
Volume | 132,438 | 15,887,049 |
Sector | Health | Media |
52-Week High | $1.82 | $777.59 |
52-Week Low | $0.48 | $525.72 |
Typical Hold Time | 17 Days | 127 Days |
Enterprise Value | $3.79M | $1.86T |
Dividend Yield | — | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
META trades at $723.54, up 0.31% on the day, with a bullish technical signal from moving averages and support at $714. The company reported strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of its Muse Spark AI model and a $21B deal with CoreWeave, driving positive sentiment.
The outlook is positive with an 80% analyst buy rating and a consensus price target of $781, but risks include ongoing youth addiction lawsuits and high capital expenditures. Revenue is projected to grow to $228.2B in 2026, supporting long-term growth despite near-term legal and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
